Notably, our analysis identified dopamine receptor D2 (DRD2)-targeting drugs, such as Apomorphine, Cabergoline, and Haloperidol, which falls in line with a limited number of trials supporting the idea that dopaminergic interventions—predominantly used for conditions such as Parkinson’s disease, schizophrenia, and bipolar mood disorder—can also change various aspects of pain perception. Here, DRD2 is linked to schizophrenia.